Aptar today announced the expansion of its operations in Mumbai, India to add local production of several pharma inhalation technologies, including Aptar’s pressurized metered dose inhaler (pMDI) ...

Aptar Beauty and BVLGARI won the Formes de Luxe Award 2026 in the Refill category. The Le Gemme Tygar Travel Spray is a custom luxury fragrance mini packaging based on the Nomad Refill technology.

Aptar Beauty’s sampling solutions and mini packaging provide reliable dispensing, portability, and a consistent brand experience. Our portfolio includes paper-based fragrance sampling, spray vials, ...

Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced the launch of Premia ™ Precision, a new quality standard for elastomer components, ...

Submit your email address below and stay up to date with the latest industry insights.

As more cough and cold products move towards self-selection, a nasal spray must do more than deliver an accurate dose. It should also feel intuitive, comfortable, and reassuring to use. This article ...

For manufacturers of complex injectable medicines, confidence in component quality depends on more than specifications. It also depends on how critical suppliers identify risk, sustain operational ...

This webinar explores how earlier system-level evidence can help reduce risk in injectable development. Hosted by Pavan Hemmege, Technical Product Manager Injectables at Aptar Pharma, and Sara Masucci ...

As quality and regulatory expectations continue to rise across the injectable pharmaceutical market, and as therapies, including biologics and GLP-1 medicines, become increasingly complex and valuable ...

For the Beauty, Personal Care, Home, Food and Beverage markets, Aptar’s experienced technical services team is proud to provide our customers with invaluable information on applying our products and ...

In today’s regulatory environment, patient safety is a priority, making contamination control and sterility essential in pharmaceutical manufacturing. The latest EMA GMP Annex 1 revision recommends ...

Particulate contamination and product cleanliness are primary concerns in the pharmaceutical market. The latest EMA GMP Annex 1 revision requires that pharmaceutical companies establish more stringent ...